Low Acceptance of Treatment in the Elderly for the Secondary Prevention of Osteoporotic Fracture in the Acute Rehabilitation Setting

Overview

Journal Aging Clin Exp Res

Publisher Springer

Specialty Geriatrics

Date 2010 Jul 17

PMID 20634646

Citations 9

Authors

Sarah D Berry

Devyani Misra

Marian T Hannan

Douglas P Kiel

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Given the high risk of subsequent fracture among elderly persons with fracture, it is important to initiate secondary treatment for osteoporosis. Acute rehabilitation centers may offer a unique opportunity to introduce treatment. Therefore, we evaluated willingness-to-participate and compliance with evidence-based interventions for the secondary prevention of osteoporotic fracture in a non-randomized study conducted in the acute rehabilitation setting. We also described differences in baseline characteristics between study participants and non-participants.

Methods: All consecutive, community dwelling admissions to an acute rehabilitation unit (Boston, MA) with the diagnosis of fracture were screened for enrollment. Eligible subjects were offered a free, 6-month supply of alendronate/cholecalciferol (70 mg/2800 IU weekly), calcium and vitamin D supplements, and fall prevention strategies. Six-month compliance (> or =75% consumption of medication or supplement) with the interventions was determined at a home visit.

Results: Among 62 eligible subjects, 25 agreed to participate. Non-participants were older than participants (86 vs 80 yrs, p<0.01). There was no significant difference between other characteristics of participants and non-participants including sex, weight, type of fracture, cognitive status, and functional status. The most common reason for non-participation was reluctance to take another medication. Among participants, only 52% were compliant with alendronate and 58% were compliant with calcium and vitamin D supplementation at 6 months.

Conclusions: Willingness- to-participate and compliance with secondary prevention strategies for osteoporosis was low in the acute rehabilitation setting, even when medications were provided free of cost. Educating individuals with fracture and their families on the consequences and treatment of osteoporosis may help to decrease the risk of sustaining a second fracture by accepting secondary preventive measures.

Citing Articles

Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.

Shi L, Min N, Wang F, Xue Q Biomed Res Int. 2019; 2019:2594149.

PMID: 31828096 PMC: 6885847. DOI: 10.1155/2019/2594149.

Patient education in osteoporosis prevention: a systematic review focusing on methodological quality of randomised controlled trials.

Morfeld J, Vennedey V, Muller D, Pieper D, Stock S Osteoporos Int. 2017; 28(6):1779-1803.

PMID: 28236127 DOI: 10.1007/s00198-017-3946-y.

Application of the health belief model and social cognitive theory for osteoporosis preventive nutritional behaviors in a sample of Iranian women.

Jeihooni A, Hidarnia A, Kaveh M, Hajizadeh E, Askari A Iran J Nurs Midwifery Res. 2016; 21(2):131-41.

PMID: 27095985 PMC: 4815367. DOI: 10.4103/1735-9066.178231.

Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study.

Emamifar A, Gildberg-Mortensen R, Andreas Just S, Lomborg N, Asmussen Andreasen R, Jensen Hansen I Int J Rheumatol. 2015; 2015:783709.

PMID: 26491449 PMC: 4603323. DOI: 10.1155/2015/783709.

Two-year adherence to treatment and associated factors in a fracture liaison service in Spain.

Naranjo A, Ojeda-Bruno S, Bilbao-Cantarero A, Quevedo-Abeledo J, Diaz-Gonzalez B, Rodriguez-Lozano C Osteoporos Int. 2015; 26(11):2579-85.

PMID: 26048675 DOI: 10.1007/s00198-015-3185-z.

References

Center J, Bliuc D, Nguyen T, Eisman J . Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007; 297(4):387-94. DOI: 10.1001/jama.297.4.387. View

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD001155. DOI: 10.1002/14651858.CD001155.pub2. View

McKinley E, Thompson J, Wilcox L, Weisman C, Andrews W . Performance indicators in women's health: incorporating women's health in the health plan employer data and information set (HEDIS). Womens Health Issues. 2002; 12(1):46-58. DOI: 10.1016/s1049-3867(01)00120-7. View

Berry S, Samelson E, Hannan M, McLean R, Lu M, Cupples L . Second hip fracture in older men and women: the Framingham Study. Arch Intern Med. 2007; 167(18):1971-6. DOI: 10.1001/archinte.167.18.1971. View

Yood R, Mazor K, Andrade S, Emani S, Chan W, Kahler K . Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med. 2008; 23(11):1815-21. PMC: 2585659. DOI: 10.1007/s11606-008-0772-0. View

Forkan R, Pumper B, Smyth N, Wirkkala H, Ciol M, Shumway-Cook A . Exercise adherence following physical therapy intervention in older adults with impaired balance. Phys Ther. 2006; 86(3):401-10. View

Mauck K, Cuddihy M, Trousdale R, Pond G, Pankratz V, Melton 3rd L . The decision to accept treatment for osteoporosis following hip fracture: exploring the woman's perspective using a stage-of-change model. Osteoporos Int. 2002; 13(7):560-4. DOI: 10.1007/s001980200073. View

Nymark T, Lauritsen J, Ovesen O, Rock N, Jeune B . Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int. 2006; 17(9):1353-7. DOI: 10.1007/s00198-006-0125-y. View

Gillespie L, Gillespie W, Robertson M, Lamb S, Cumming R, Rowe B . Interventions for preventing falls in elderly people. Cochrane Database Syst Rev. 2003; (4):CD000340. DOI: 10.1002/14651858.CD000340. View

10.

Curtis J, Xi J, Westfall A, Cheng H, Lyles K, Saag K . Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009; 47(3):334-41. PMC: 2693955. DOI: 10.1097/MLR.0b013e31818afa1c. View

11.

Klotzbuecher C, Ross P, Landsman P, Abbott 3rd T, Berger M . Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15(4):721-39. DOI: 10.1359/jbmr.2000.15.4.721. View

12.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD004523. DOI: 10.1002/14651858.CD004523.pub3. View

13.

Feldstein A, Elmer P, Orwoll E, Herson M, Hillier T . Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med. 2003; 163(18):2165-72. DOI: 10.1001/archinte.163.18.2165. View

14.

Feldstein A, Schneider J, Smith D, Vollmer W, Rix M, Glauber H . Harnessing stakeholder perspectives to improve the care of osteoporosis after a fracture. Osteoporos Int. 2008; 19(11):1527-40. DOI: 10.1007/s00198-008-0605-3. View

15.

Nguyen-Oghalai T, Kuo Y, Zhang D, Graham J, Goodwin J, Ottenbacher K . Discharge setting for patients with hip fracture: trends from 2001 to 2005. J Am Geriatr Soc. 2008; 56(6):1063-8. PMC: 2441644. DOI: 10.1111/j.1532-5415.2008.01688.x. View

16.

Ottenbacher K, Hsu Y, Granger C, Fiedler R . The reliability of the functional independence measure: a quantitative review. Arch Phys Med Rehabil. 1996; 77(12):1226-32. DOI: 10.1016/s0003-9993(96)90184-7. View

17.

Giangregorio L, Papaioannou A, Thabane L, DeBeer J, Cranney A, Dolovich L . Do patients perceive a link between a fragility fracture and osteoporosis?. BMC Musculoskelet Disord. 2008; 9:38. PMC: 2329635. DOI: 10.1186/1471-2474-9-38. View

18.

Gardner M, Brophy R, Demetrakopoulos D, Koob J, Hong R, Rana A . Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. J Bone Joint Surg Am. 2005; 87(1):3-7. DOI: 10.2106/JBJS.D.02289. View

19.

Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A . Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine. 2007; 75(3):303-10. DOI: 10.1016/j.jbspin.2007.07.011. View

20.

Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C . Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18):1799-809. PMC: 2324066. DOI: 10.1056/NEJMoa074941. View